Video Library

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.

We are excited to bring you new information in our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom introduces us to Dr. Elizabeth Kessler, from the University of Coloradeo Cancer Center. For more information on Dr. Kessler, please visit her bio here. In part one of

Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.

GRACE is happy to present our ASCO 2016 Lung Cancer Roundtable series, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most

Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses using adjuvant chemotherapy for elderly and frail patients. What was seen in particular in the trial performed by NCI Canada, using cisplatin with navelbine chemotherapy, was that people who were considered elderly were able to

For our 5th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss the most appropriate treatment for elderly patients with advanced NSCLC, and whether age alters the recommendations.

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.

For our 7th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss the best treatment for frail patients with advanced NSCLC.

For our 15th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss treating later stage small cell lung cancer.

For our 17th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss first line therapy for NSCLC patients that have anaplastic lymphoma kinase (ALK) positive.